AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Kazia Therapeutics Ltd ADR (NASDAQ:KZIA)
0.965 USD
+0.010 1.047%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.955 |
|---|---|
| Change | +0.010 1.047% |
| 52 W H/L (in USD) | 1.340/0.187 |
| EBITDA (in USD) | -17.524M |
| PE Ratio | -- |
| Volume | 20912 |
| Diluted Eps TTM | -0.35 |
| Total Assets (in USD) | 28.085M |
|---|---|
| Total Liabilities (in USD) | 16.035M |
| Revenue TTM (in USD) | 0.001M |
| Cash (in USD) | 5.241M |
| Market Cap (in USD) | 7.244 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | 0.001M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.
Three International Towers, Sydney, NSW, Australia, 2000
1300 787 272
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc ( | CEO, MD & Exec. Director | 1973 |
| 2. | Ms. Karen R. Krumeich | Chief Financial Officer | 1954 |
| 3. | Dr. John E. Friend II, M.D. | Chief Medical Officer | 1970 |
| 4. | Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD | Company Sec. | 1959 |
| 5. | Dr. John Edwin Friend II, M.D. | CEO, MD & Director | 1970 |
| 6. | Ms. Gabrielle Heaton BBUS (ACC), CPA | Principal Accounting Officer, VP of Finance & Administration and Principal Financial Officer | NA |
| 7. | Ms. Anna Sandham | Company Secretary | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-1.980 2.445% | 80.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-2.160 2.668% | 80 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+0.290 0.057% | 512.01 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+7.400 1.113% | 663.67 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -20.736M | -25.016M | -8.906M | -12.765M | -10.568M |
| Minority Interest | - | - | - | - | 0M |
| Net Income | -20.465M | -24.648M | -8.422M | -12.467M | -10.27M |
| Selling General Administrative | 8.583M | 4.511M | 7.022M | 3.69M | 3.786M |
| Gross Profit | - | 0M | 15.183M | 0.001M | 0.002M |
| Reconciled Depreciation | 1.869M | 1.953M | 1.265M | 1.084M | 1.084M |
| Ebit | -24.124M | -26.696M | -3.808M | -12.525M | -8.38M |
| Ebitda | -27.535M | -24.743M | -2.543M | -11.441M | -7.296M |
| Depreciation And Amortization | -3.411M | 1.953M | 1.265M | 1.084M | 1.084M |
| Operating Income | -24.124M | -26.696M | -3.808M | -12.525M | -8.38M |
| Other Operating Expenses | 24.147M | 24.881M | 21.561M | 13.162M | 10.253M |
| Interest Expense | - | 0.002M | 5.098M | 0.24M | 2.188M |
| Tax Provision | -0.271M | -0.368M | -0.484M | -0.298M | -0.298M |
| Interest Income | 0.023M | 0.002M | 0.042M | 0.066M | 0.1M |
| Net Interest Income | 0.023M | 0.002M | 0.042M | 0.066M | 0.1M |
| Income Tax Expense | -0.271M | -0.368M | -0.484M | -0.298M | -0.298M |
| Total Revenue | 0M | 0M | 15.183M | 0.001M | 0.002M |
| Total Operating Expenses | 24.147M | 24.881M | 21.561M | 13.162M | 10.253M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 3.388M | 1.68M | -5.098M | -0.24M | -2.188M |
| Net Income From Continuing Ops | -20.465M | -24.648M | -8.422M | -12.467M | -10.27M |
| Net Income Applicable To Common Shares | -20.465M | -24.648M | -8.422M | -12.467M | -10.27M |
Balance Sheet
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Total Assets | 28.085M | 34.959M | 58.088M | 23.063M | 21.177M |
| Intangible Assets | 17.269M | 20.05M | 22.003M | 12.41M | 13.494M |
| Other Current Assets | 3.794M | 0.196M | 1.728M | 0.695M | 0.529M |
| Total Liab | 16.035M | 16.32M | 20.237M | 8.938M | 6.982M |
| Total Stockholder Equity | 12.051M | 18.638M | 37.851M | 14.125M | 14.195M |
| Other Current Liab | 0.75M | 3.161M | 6.434M | 3.373M | 0.85M |
| Common Stock | 97.452M | 84.48M | 80.29M | 48.781M | 36.642M |
| Capital Stock | 97.452M | 84.48M | 80.29M | 48.781M | 36.642M |
| Retained Earnings | -89.083M | -68.254M | -44.204M | -36.186M | -24.948M |
| Good Will | - | - | - | - | 0M |
| Other Assets | 0.043M | 7.301M | 6.694M | - | 0M |
| Cash | 5.241M | 7.361M | 27.587M | 8.764M | 5.434M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 7.565M | 4.685M | 8.327M | 5.067M | 1.9M |
| Current Deferred Revenue | 4.161M | - | - | - | - |
| Net Debt | -3.445M | -7.361M | -27.587M | -8.764M | -5.434M |
| Short Term Debt | 1.797M | - | - | - | 0M |
| Short Long Term Debt | 1.797M | - | - | - | 0M |
| Short Long Term Debt Total | 1.797M | - | - | - | 0M |
| Other Stockholder Equity | 4.423M | 0.002M | 0.464M | 0.464M | 0.464M |
| Property Plant Equipment | - | - | - | - | 0M |
| Total Current Assets | 10.773M | 7.608M | 29.391M | 10.653M | 7.515M |
| Long Term Investments | - | - | - | 0M | 0.168M |
| Short Term Investments | - | - | - | - | 0M |
| Net Receivables | 0.106M | 0.051M | 0.076M | 1.194M | 1.552M |
| Long Term Debt | - | - | - | - | 0M |
| Inventory | - | - | - | - | 0M |
| Accounts Payable | 0.857M | 1.524M | 1.893M | 1.694M | 1.05M |
| Accumulated Other Comprehensive Income | -0.742M | 2.412M | 1.301M | 1.066M | 2.037M |
| Non Currrent Assets Other | 0.043M | 7.301M | 6.694M | - | 13.662M |
| Non Current Assets Total | 17.312M | 27.351M | 28.697M | 12.41M | 13.662M |
| Capital Lease Obligations | - | - | - | - | 0M |
| Long Term Debt Total | - | - | - | - | 0M |
Cash Flow
(Currency in USD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | 0M | -2.365M | 0M | 0M | 2.359M |
| Total Cashflows From Investing Activities | - | -2.365M | -2.365M | -2.365M | 2.359M |
| Total Cash From Financing Activities | 12.972M | 3.726M | 28.109M | 12.14M | 3.816M |
| Net Income | -20.465M | -24.648M | -8.422M | -12.467M | -10.27M |
| Change In Cash | -2.12M | -20.226M | 18.823M | 3.33M | -0.522M |
| Begin Period Cash Flow | 7.361M | 27.587M | 8.764M | 5.434M | 5.956M |
| End Period Cash Flow | 5.241M | 7.361M | 27.587M | 8.764M | 5.434M |
| Total Cash From Operating Activities | -15.156M | -22.761M | -9.111M | -8.81M | -6.714M |
| Depreciation | 1.869M | 1.953M | 1.265M | 1.084M | 1.084M |
| Other Cashflows From Investing Activities | - | -2.365M | -2.365M | -2.365M | 2.359M |
| Dividends Paid | - | - | - | - | 0M |
| Change To Inventory | - | - | - | - | 0M |
| Sale Purchase Of Stock | - | - | - | - | 3.816M |
| Other Cashflows From Financing Activities | -0M | -2.365M | -1.673M | -0.833M | 2.359M |
| Capital Expenditures | 0M | 0M | 0M | 0M | 0M |
| Change In Working Capital | 4.332M | -0.104M | -5.59M | 1.669M | 0.353M |
| Other Non Cash Items | -2.097M | -1.637M | 2.569M | 0.474M | 0.062M |
| Free Cash Flow | -15.156M | -22.761M | -9.111M | -8.81M | -6.714M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Nasdaq Composite Index | 11 months ago | 4948 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Morgan Stanley - Brokerage Accounts | 1 year ago | 201550 |
| 2. | Bank of Montreal | 1 year ago | 140166 |
| 3. | BMO Capital Markets Corp. | 1 year ago | 140166 |
| 4. | HSBC Holdings PLC | 11 months ago | 63956 |
| 5. | TWO SIGMA SECURITIES, LLC | 1 year ago | 58423 |
| 6. | XTX Topco Ltd | 1 year ago | 19436 |
| 7. | BNP Paribas Arbitrage, SA | 1 year ago | 12700 |
| 8. | Rhumbline Advisers | 1 year ago | 9710 |
| 9. | Goss Wealth Management LLC | 1 year ago | 500 |
| 10. | SIMPLEX TRADING, LLC | 1 year ago | 190 |
| 11. | UBS Group AG | 1 year ago | 100 |
| 12. | Hanson Mcclain Inc | 1 year ago | 87 |
| 13. | AdvisorNet Financial, Inc | 1 year ago | 5 |
| 14. | Acadian Asset Management LLC | 11 months ago | 0 |
| 15. | Steward Partners Investment Advisory, LLC | 1 year ago | 0 |
| 16. | Junked Platinum Investment Management Ltd | 11 months ago | 0 |
| 17. | Armistice Capital, LLC | 11 months ago | 0 |
| 18. | Virtu Financial LLC | 11 months ago | 0 |
| 19. | McGlone Suttner Wealth Management Inc | 11 months ago | 0 |
| 20. | Bank of America Corp | 1 year ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
